Clinical Trial Update: A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of LGK974, a Wnt pathway inhibitor, in malignancies dependent on Wnt ligands; the study included several cancers such as pancreati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Squamous Cell Carcinoma
• Colorectal Cancer
• Esophageal Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Pancreatic Cancer
• Squamous Cell Carcinoma of the Lung
• Triple-negative Breast Cancer

Drugs mentioned

• LGK974 (WNT974)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pancreatic Cancer, BRAF Mutant Colorectal Cancer | Phase 1 | Status: COMPLETED